What is Cardiogen?
Cardiogen is a synthetic four-amino-acid bioregulator identified as Ala-Glu-Asp-Arg (AEDR). It belongs to a family of short peptides developed around proposed tissue-specific signaling.[6][12]
Its cardiac focus comes from experiments on myocardium, the muscle tissue that contracts to pump blood. Other experiments examine the proteins that give cells their shape and support the cell nucleus.[1][6]
Cardiogen’s four-amino-acid AEDR sequence differs from the three-amino-acid sequence AED. It also differs from CardioGen-82, the rubidium-based diagnostic product with a similar name.[6][15]
What Cardiogen is investigated for
Cardiogen evidence is grouped by practical use case and oral and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.
Evidence snapshot
Overall confidence
Heart-tissue biology provides a plausible rationale. Clinical benefits for heart function or cardiovascular-event prevention remain unestablished.[1][6][5]
Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.
Human evidence
Human evidence for an independent cardiac treatment benefit remains limited.[5][17]
Animal / preclinical
Preclinical findings concern heart-cell growth and cellular stress; clinical repair benefits remain uncertain.[1][2][3][4]
Mechanism support
Cardiogen may influence heart-cell growth and stress responses, including p53 signaling involved in cell survival.[1]
Forms & administration
Cardiogen has oral capsules and lingual drops, with product-specific preparation and amounts. Intramuscular formulations remain experimental and animal-only.[13][14][18]
Dosing & protocols
These ranges are general reference points, not personal dosing instructions.
Safety profile
Small combined-care reports do not establish common side-effect rates or interactions with heart medicines. Cell and animal findings cannot supply those human safety estimates.[5][17]
Regulatory status
United States
The Cardiogen peptide bioregulator is distinct from CardioGen-82, the rubidium-based diagnostic product. That medicine’s approval does not apply to AEDR capsules or peptide preparations.[15][6]
| Route | FDA drug approval | 503A compounding |
|---|---|---|
| Oral | Not Approved The Cardiogen peptide bioregulator is distinct from CardioGen-82, the rubidium-based diagnostic product. That medicine’s approval does not apply to AEDR capsules or peptide preparations.[15][6] | Not Reviewed Compounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions. |
Oral
FDA drug approval
Not ApprovedThe Cardiogen peptide bioregulator is distinct from CardioGen-82, the rubidium-based diagnostic product. That medicine’s approval does not apply to AEDR capsules or peptide preparations.[15][6]
503A compounding
Not ReviewedCompounding eligibility for this specific preparation has not been confirmed. Drug approval and compounding eligibility are separate questions.
International
Medicinal-product authorization outside the United States remains unconfirmed for the named preparation; status depends on the exact product and country.[15]
Sports & competition
WADA S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no later section addresses them. An unapproved peptide preparation is not athlete-cleared.
How it works
Cardiogen may influence heart-cell growth and stress responses, including p53 signaling involved in cell survival.[1]
AEDR may also affect structural proteins such as actin and tubulin, which help cells maintain their shape and support the nucleus. These are proposed cell-maintenance mechanisms.[6][7]
Research gaps & open questions
What the current literature has not yet settled about Cardiogen:
Controlled trials need to measure symptoms, exercise capacity or cardiac function alongside usual treatment, so that any benefit beyond standard care can be estimated.[5][17]
Human studies need to measure absorption and tissue exposure after an identified AEDR product. Computer predictions about peptide transport cannot establish that capsules deliver an active amount to the heart.[7]
Repeated-course studies need to establish adverse effects and interactions with cardiovascular medicines; the small adjunctive reports cannot quantify those risks.[5][17]
Common questions
Is Cardiogen the three-amino-acid peptide AED?
No. Cardiogen is identified as the four-amino-acid sequence AEDR. The three-amino-acid sequence AED is a different molecule.[6]
History & discovery
Cardiogen emerged from the tissue-specific short-peptide program. Its early cardiac rationale came from organ cultures rather than a patient trial or an approved heart medicine.[3][1]
Investigators examined proliferation and cell-death signaling in heart explants from young and old rats. The findings supported further study of cellular maintenance, without measuring heart function in patients.[1]
A cell study examined the AEDR sequence, while a separate regional report described capsules in twelve patients receiving usual cardiovascular care. The clinical design could not establish an independent treatment effect.[6][5]
18 citations
Cardiogen research focuses on heart-muscle cell maintenance and cellular stress. Clinical evidence remains preliminary, with no established improvement in cardiac pumping function or prevention of cardiovascular events.[1][6][5][7][17][18]
